ARS Pharmaceuticals, Inc. (SPRY)
NGM · Healthcare · Biotechnology
$9.76
+1.77%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$843.1M
P/S (TTM)
8.5x
Exchange
NGM
About ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 15.7M | 32.5M | 28.1M | 22.7M |
| Gross Profit | 10.7M | 24.3M | 21.9M | 16.4M |
| Operating Income | -47.6M | -53.2M | -41.5M | -60.1M |
| Net Income | -44.9M | -51.2M | -41.3M | -60.6M |
| Diluted EPS | $-0.46 | $-0.52 | $nan | $-0.61 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 1.3M | 30K | 89.1M | 84.3M |
| Gross Profit | 30K | 88.2M | 63.9M | |
| Operating Income | -35.5M | -67.5M | -3.1M | -179.4M |
| Net Income | -34.7M | -54.4M | 8.0M | -171.3M |
| Diluted EPS | $-0.87 | $-0.57 | $0.08 | $nan |